CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP

Abstract

With respect to myelotoxicity, 131 I-RIT had the lowest incidence of grade 3/4 neutropenia and, conversely, the highest incidence of grade 3/4 thrombocytopenia. The lowest incidence of thrombocytopenia was observed with RCHOP and was consistent across trials. MDS/AL was reported at 5-yr follow up in a single study; 1 MDS in a patientreceiving BR and 1 AL in a patient-receiving RCHOP. This study also reported the highest incidence of second malignancy 8% and 9% with respect to BR and RCHOP.Conclusion: Based upon 10-year follow-up, iodine-131-rituximab radioimmunotherapy is apparently on this analysis the most efficacious, most affordable and most practical of all published induction therapies for advanced follicular lymphoma.